Pfizer – A giant in the pharmaceutical industry

In the realm of the pharmaceutical industry within the United States, Pfizer has demonstrated an unwavering commitment to progress and innovation, exemplified by their remarkable achievements such as the development of the COVID-19 vaccine. A pertinent inquiry arises: has this industry titan truly advanced its standing in the sphere of oncological therapeutic offerings through recent endeavors?

1. Overview

Pfizer is one of the world’s largest multinational pharmaceutical corporations with an operating history of more than 174 years. It was founded in 1849 in New York City by two German business cousins.

In the early years, Pfizer only focused on the field of chemical production, but the resounding success of making Santonin Worm Treatment, followed by Citric Acid, brought huge profits. One of the premises that helps Pfizer expand to other areas of New York City.

Up to now, the company has more than 36 manufacturing plants globally and more than 100 representative offices spread across 59 countries.

2. Development cooporation

Pfizer has ownership of:

  • 49 companies
  • 105 investments
  • Partner with research institutes and many large companies such as Javelin Biotech, Vivet Therapeutics to promote research and production.

2020 – A year that marked a new development step for Pfizer when it cooperated with BioNTech, a pharmaceutical company in Germany and successfully launched Corminaty, one of the most popular anti-COVID 19 vaccines till now.

3. Research and development activities

Currently, Pfizer has produced/distributed a total of over 300 products including drugs and vaccines in the fields of: Cancer, Infections, Immunology, Cardiology, Neurology. Among them, oral tablets, injection solution and lyophilized powder for injection are 3 common dosage forms. Pfizer holds 412 technologies related to drug delivery systems and 15 new drug discovery technologies.

4. Development plan

As of the present, the corporation remains committed to the advancement of preventive measures against COVID-19 and other diseases through collaborative efforts with various governments and global enterprises. Furthermore, Pfizer has a steadfast determination to foster research initiatives encompassing oral antiviral treatments, in addition to their ongoing vaccine research endeavors aimed at mitigating the emergence of novel viral variants.

With their expertise across fields such as cancer, rare diseases, internal medicine,… Pfizer is committed to focusing on enhancing and improving pharmaceutical therapies to change the lives of more patients.

The company expects revenue growth of 7 – 9% excluding sales of COVID-19 vaccines in 2023 when the majority of potential products are expected to launch in the second half of the year. Pfizer also expects to launch 19 vaccines and treatments over the next 18 months.

The pharmaceutical sector consistently observes robust growth dynamics within the domain of cancer treatment medications, which represents a prospective field with considerable revenue generation potential and profit prospects. Acknowledging this potential benefits, Pfizer acquired Seagen in March 2023, a biotechnology company specializing in cancer treatment research, for $43 billion. The acquisition is consequently expected to enhance Pfizer’s position globally.


REFERENCES:

  1. Pfizer
  2. Tập đoàn dược phẩm sinh học Pfizer chia cổ tức quý II năm 2023
  3. Tổng giám đốc Pfizer cam kết đưa nhiều loại vaccine đến Việt Nam
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments
error: Content is protected !!